NDAORALTABLET
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
DAYPRO (oxaprozin) by Pfizer is cyclooxygenase inhibitors [moa]. First approved in 1992.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYPRO (oxaprozin) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for the treatment of osteoarthritis, rheumatoid arthritis, and other inflammatory conditions. This small-molecule NSAID has been on the market since 1992 and represents a mature therapeutic option in a crowded pain management category.
$0.035BPart D
LOE ApproachingDeclining
With lifecycle status approaching loss of exclusivity and minimal Part D spending, the DAYPRO brand team is likely small and focused on defensive positioning rather than growth initiatives.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Started Nov 2017
12 enrolled
Healthy
Career Relevance
Working on DAYPRO offers limited career growth potential given its mature, declining market position and approaching loss of exclusivity. Roles on this product typically focus on defensive market maintenance, generic transition planning, and cost management rather than innovation or expansion, making it a consolidation play rather than a career-building opportunity.
Brand Manager
Worked on DAYPRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.